Diagnostic Performance of the 2018 EASL vs. LI-RADS for Hepatocellular Carcinoma Using CT and MRI: A Systematic Review and Meta-Analysis of Comparative Studies

Diagnosis of focal liver lesions from ultrasound images using a pretrained residual neural network

OBJECTIVE

This study aims to develop a ResNet50-based deep learning model for focal liver lesion (FLL) classification in ultrasound images, comparing its performance with other models and prior research.

METHODOLOGY

We retrospectively collected 581 ultrasound images from the Chulabhorn Hospital's HCC surveillance and screening project (2010-2018). The dataset comprised five classes: non-FLL, hepatic cyst (Cyst), hemangioma (HMG), focal fatty sparing (FFS), and hepatocellular carcinoma (HCC). We conducted 5-fold cross-validation after random dataset partitioning, enhancing training data with data augmentation. Our models used modified pre-trained ResNet50, GGN, ResNet18, and VGG16 architectures. Model performance, assessed via confusion matrices for sensitivity, specificity, and accuracy, was compared across models and with prior studies.

RESULTS

ResNet50 outperformed other models, achieving a 5-fold cross-validation accuracy of 87 ± 2.2%. While VGG16 showed similar performance, it exhibited higher uncertainty. In the testing phase, the pretrained ResNet50 excelled in classifying non-FLL, cysts, and FFS. To compare with other research, ResNet50 surpassed the prior methods like two-layered feed-forward neural networks (FFNN) and CNN+ReLU in FLL diagnosis.

CONCLUSION

ResNet50 exhibited good performance in FLL diagnosis, especially for HCC classification, suggesting its potential for developing computer-aided FLL diagnosis. However, further refinement is required for HCC and HMG classification in future studies.

Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis

Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.